Kiromic BioPharma, Inc. (KRBP)
OTCMKTS
· Delayed Price · Currency is USD
1.615
-0.315 (-16.32%)
Feb 20, 2025, 3:00 PM EST
Kiromic BioPharma Employees
Kiromic BioPharma had 44 employees as of December 31, 2024. The number of employees increased by 9 or 25.71% compared to the previous year.
Employees
44
Change (1Y)
9
Growth (1Y)
25.71%
Revenue / Employee
n/a
Profits / Employee
-$105,136
Market Cap
2.48M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Endo Inc. | 2,931 |
Elite Pharmaceuticals | 64 |
Glass House Brands | 413 |
CytoDyn | 9 |
Northwest Biotherapeutics | 25 |
Silence Therapeutics | 109 |
SANUWAVE Health | 31 |
Kiromic BioPharma News
- 4 days ago - Kiromic BioPharma Reports Patient 4 in Deltacel-01 Clinical Trial Reaches 10-Month Progression-Free Survival - Business Wire
- 4 weeks ago - Kiromic BioPharma Reports Tumor Volume Decrease in Two Patients Enrolled in Deltacel-01 - Business Wire
- 2 months ago - Kiromic BioPharma Reports 32% Decrease in Tumor Volume Eight Months Post-Treatment in Fourth Patient Enrolled in Deltacel-01 - Business Wire
- 2 months ago - Financial Crime Weekly: CEO Sentenced To 51 Months In Prison, Kiromic BioPharma Charged With Failure To Disclose Material Information - Benzinga
- 2 months ago - Kiromic BioPharma Announces Settlement of Previously Disclosed SEC Investigation - Business Wire
- 2 months ago - SEC Charges Kiromic BioPharma and Two Former C-Suite Executives with Misleading Investors about Status of FDA Reviews - Newsfile Corp
- 4 months ago - Kiromic BioPharma Reports Favorable Ongoing Clinical Results From Fourth and Sixth Patients Enrolled in Deltacel-01 - Business Wire
- 5 months ago - Kiromic BioPharma Reports Favorable 10-Month Follow-Up Results for the First Patient Treated in its Deltacel-01 Clinical Trial - Business Wire